|Description||Synthetic decapeptide antagonist to gonadotropin releasing hormone (GnRH). It is marketed by Praecis Pharmaceuticals as Plenaxis. Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the market.|
|DrugBank||Primary Accession Number: DB00106|
|Type||Approved, Biotech, Investigational, Withdrawn|
|Indication||For palliative treatment of advanced prostate cancer.|
|Mechanism of Action||Abarelix binds to the gonadotropin releasing hormone receptor and acts as a potent inhibitor of gonadotropin secretion.|
|Absorption||Following IM administration of 100 mg, abarelix is absorbed slowly with a mean peak concentration of 43.4 ng/mL observed approximately 3 days after the injection.|
|Toxicity||The maximum tolerated dose of abarelix has not been determined. The maximum dose used in clinical studies was 150 mg. There have been no reports of accidental overdose with abarelix.|
You need to load/activate the cURL extension (http://www.php.net/cURL).